发明名称 |
Anti-IL-23 heterodimer specific antibodies |
摘要 |
The present disclosure provides an isolated or recombinant IL-23-binding protein comprising an antigen binding domain of an antibody, wherein the antigen binding domain specifically binds to IL-23 but does not significantly bind to an IL-12p40 subunit and does not significantly bind to an IL-23p19 subunit when they are not components of IL-23. The present disclosure also provides uses of the IL-23-binding protein. |
申请公布号 |
US9127057(B2) |
申请公布日期 |
2015.09.08 |
申请号 |
US201113810474 |
申请日期 |
2011.07.20 |
申请人 |
Teva Pharmaceuticals Ausralia Pty Ltd |
发明人 |
Clarke Adam William;Doyle Anthony G.;Pollard Matthew;Tran Stephen |
分类号 |
A61K39/395;C07K16/24;A61K39/00 |
主分类号 |
A61K39/395 |
代理机构 |
Stradley Ronon Stevens & Young, LLP |
代理人 |
Stradley Ronon Stevens & Young, LLP |
主权项 |
1. An isolated or recombinant antibody or antigen-binding fragment thereof that specifically binds to IL-23, comprising a heavy chain CDR1comprising the amino acid sequence of SEQ ID NO: 8, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 9 or 22, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 10, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 13, a light chain CDR2comprising the amino acid sequence of SEQ ID NO: 14, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 15. |
地址 |
Macquarie Park, NSW AU |